• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
In the last 2 hours
In the last 8 hours
Earlier today
In the last 7 days
Wall St lower in aftermath of global tech outage The West Australian22:03 21-Jul-24
Tirzepatide Reduced Disordered Breathing in Patients With Sleep Apnea Journal of American Medical Associations18:45 19-Jul-24
Is Viking Therapeutics a Millionaire-Maker? The Motley Fool11:00 19-Jul-24
German CDMO outlays $980m on GLP-1 manufacturing expansion Pharmaceutical Technology05:14 17-Jul-24
In the last month
Tanishq hopes for duty rationalisation on gold imports The Financial Express21:12 15-Jul-24
Zee gets shareholder approval to raise Rs. 2000 crore The Financial Express19:51 15-Jul-24
Zomato’s Deepinder Goyal enters the billionaire club The Financial Express17:27 15-Jul-24
27 establishments surrender exemption under EPFO The Financial Express05:24 15-Jul-24
Is Eli Lilly a Good Dividend Stock to Buy Now? The Motley Fool11:32 14-Jul-24
Counterfeit Ozempic Is on the Rise Yahoo! UK & Ireland15:29 13-Jul-24
Finding Diet Drugs That Work Columbia University Department of Surgery18:24 12-Jul-24
Pfizer moves forward with once-daily weight loss pill Clinical Trials Arena16:39 11-Jul-24
view more headlines
23 Jul 17:15

About our Tirzepatide news

Latest news on Tirzepatide, a drug that is being developed as a potential treatment for obesity and type 2 diabetes. It is a synthetic hormone that is designed to mimic the effects of natural hormones called incretins, which help to lower blood sugar and reduce appetite. Tirzepatide has shown promise in clinical trials, producing significant weight loss in people with obesity or type 2 diabetes. It is administered as a once-weekly injection, and it is believed to work by increasing the production of a hormone called GLP-1, which helps to regulate appetite and insulin production. Tirzepatide is currently in late-stage clinical trials, and it is expected to be considered for regulatory approval in the coming years.

Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.